caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1649492448

Shahram AbrishamyM.D.

Family PracticeMarina Del Rey, CAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
QUALITY · MIPS · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
42
Beneficiaries
—
Total drug cost
$959
Distinct drugs
3
Brand share
0.0%
Top prescribed drugs
Triamcinolone Acetonide19 claims
Clobetasol Propionate12 claims
Methylprednisolone11 claims
REFERRAL NETWORK

Where Shahram Abrishamy's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 3 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Bernard Raskin
Dermatology · Valencia, CA
47167
Unilab Corporation
Clinical Laboratory · West Hills, CA
1330
Manjunath Vadmal
Pathology · Burbank, CA
1216
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$768
Payment records
18
By payment type
Food and Beverage$768
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
255
Unique beneficiaries
—
Total services
678
Distinct HCPCS
8
Medicare payment
$24K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 8,228 Family Practice providers in CA — above median (cohort median 411).